Experimental Therapeutics Program News Today

Aliasger K. Salem’s profile on The Conversation

Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.

Physicians in the O’Neal Comprehensive Cancer Center at UAB are advancing the field of thyroid care with cutting-edge, patient-specific procedures and collaborative research investigations. Written by: Julie Cole Miller...

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Lindsay Kilburn, MD, discusses key efficacy findings from the phase 2 FIREFLY-1 trial of the investigational type II RAF inhibitor tovorafenib (DAY101) in heavily pretreated pediatric patients with low-grade glioma.

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.

Bryan Allen, MBA, MD, PhD, has been appointed chair and departmental executive officer (DEO) of the Department of Radiation Oncology in the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

Faculty across 4 institutions discuss their participation in a 4-team initiative launched by Stand Up To Cancer® that focuses on expanding access to cancer care and research.

To expand access to cancer care and research, Stand Up to Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.